Repository logo
 
Publication

Biomarkers in renal cell carcinoma: a metabolomics approach

dc.contributor.authorMonteiro, Márcia Sá
dc.contributor.authorCarvalho, Márcia
dc.contributor.authorBastos, Maria de Lourdes
dc.contributor.authorGuedes de Pinho, Paula
dc.date.accessioned2021-07-02T11:15:11Z
dc.date.available2021-07-02T11:15:11Z
dc.date.issued2014
dc.description.abstractSince Otto Warburg, many studies have explored the unique metabolic phenotype of cancer cells highlighting the value and applicability of metabolomics in the oncology field, particularly in the development of cancer biomarkers. With respect to renal cell carcinoma (RCC), a metabolomics approach would own a great potential since urinary system is intimately connected with urine and, this biofluid, offers some advantages allowing the development of an assay suitable for use in clinical practice. Moreover, the assessment of metabolic derangements characteristics of RCC might provide a complete health assessment of this pathology, enabling the development of novel targeted therapies and even the stratification of responsive patients to specific therapeutic options improving the effectiveness of therapy. Metabolomic studies performed so far showed that the RCC metabolic signature is characterized by alterations in metabolites related to energy metabolic pathways, particularly glycolysis, amino acid and fatty acid catabolism, known to be crucial to cell proliferation. Despite some of those alterations are common to carcinogenesis, the potential role of acylcarnitines, gentisate, α-ketoglutarate and quinolinate in RCC pathophysiology has been proposed recently. The ability of metabolomics to discriminate between RCC and normal samples shows convincing evidence of its applicability in RCC management. Furthermore, the studies already carried out have not only tried to unveil the metabolic profile of RCC but also to evaluate the impact of some factors, namely technical, in RCC-metabolomics research. This type of study is pivotal in the design of metabolomics studies, helping to increase the reliability of the results. The present review updates the current knowledge on the metabolic alterations recognized in the RCC, and provides insight to the characteristics, strengths, limitations, and recent advances in RCC-metabolomics studies, always keeping in mind its potential application in clinical/health areas as a biomarker discovery tool.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1007/s11306-014-0659-5pt_PT
dc.identifier.issn1573-3882
dc.identifier.urihttp://hdl.handle.net/10284/10019
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.relationThe authors thank the Fundação para a Ciência e a Tecnologia (FCT) for financial support through projects PestC/ EQB/LA0006/2011 and Pest-OE/QUI/UI0612/2013. Márcia Sá Monteiro acknowledges FCT for her PhD grant (SFRH/BD/80518/ 2011).pt_PT
dc.subjectRenal cell carcinomapt_PT
dc.subjectMetabolomicspt_PT
dc.subjectMetabolic signaturept_PT
dc.subjectBiomarker discoverypt_PT
dc.titleBiomarkers in renal cell carcinoma: a metabolomics approachpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1222pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage1210pt_PT
oaire.citation.titleMetabolomicspt_PT
oaire.citation.volume10pt_PT
person.familyNameCarvalho
person.givenNameMarcia
person.identifier2017111
person.identifier.ciencia-id8B10-171E-E63E
person.identifier.orcid0000-0001-9884-4751
person.identifier.ridD-5999-2013
person.identifier.scopus-author-id7201413997
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3837b828-ba57-47f7-a811-cce65e4922c6
relation.isAuthorOfPublication.latestForDiscovery3837b828-ba57-47f7-a811-cce65e4922c6

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Biomarkers in renal cell carcinoma.pdf
Size:
790.85 KB
Format:
Adobe Portable Document Format